

Anti-EphA3 Reference Antibody (ifabotuzumab)

Recombinant Antibody Catalog # APR10514

Product Information

Application FC, Kinetics, Animal Model

Primary Accession P29320

Reactivity Human, Mouse Clonality Monoclonal Isotype IgG1

Calculated MW 110131

Additional Information

Target/Specificity EphA3

Endotoxin

Conjugation Unconjugated

Expression system CHO Cell

Format Purified monoclonal antibody supplied in PBS, pH6.0, without

preservative. This antibody is purified through a protein A column.

Protein Information

Name EPHA3

Synonyms ETK, ETK1, HEK, TYRO4

Function Receptor tyrosine kinase which binds promiscuously membrane- bound

ephrin family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Highly promiscuous for ephrin-A ligands it binds preferentially EFNA5. Upon activation by EFNA5 regulates cell-cell adhesion, cytoskeletal organization and cell migration. Plays a role in cardiac cells migration and differentiation and regulates the formation of the atrioventricular canal and septum during development probably through activation by EFNA1. Involved in the retinotectal mapping of neurons. May also control the segregation but not the guidance of motor and sensory axons during neuromuscular circuit


development.

Cellular Location [Isoform 1]: Cell membrane; Single-pass type I membrane protein


Widely expressed. Highest level in placenta.

Tissue Location

Images



Anti-EphA3 Reference Antibody (ifabotuzumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-EphA3 Reference Antibody (ifabotuzumab)is more than 95% ,determined by SEC-HPLC.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.